Business Context and Reporting Period
Company: Alphatec Holdings, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2007
Business Overview: Alphatec designs, develops, manufactures, and markets spinal surgery implants (screws, rods, spacers, plates) primarily in the United States and Japan. The company operates through its subsidiary, Alphatec Spine, Inc.
Key Financial Metrics
| Metric (in thousands) | Q1 2007 | Q1 2006 |
|---|---|---|
| Revenues | $19,550 | $18,029 |
| Gross Profit | $12,669 | $11,619 |
| Gross Margin | 64.8% | 64.4% |
| Operating Loss | $(2,612) | $(3,111) |
| Net Loss | $(2,674) | $(5,876) |
| Net Loss per Share (Basic/Diluted) | $(0.08) | $(0.42) |
| Cash and Cash Equivalents | $8,090 | $790 |
| Total Debt (Current + Long-term) | $7,486 | $8,334 |
| Net Cash Used in Operating Activities | $(4,931) | $(1,873) |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 8.4% ($1.6 million) driven by a $2.2 million expansion in the U.S. sales network (Zodiac, Novel, Solanas products). This was partially offset by a $0.7 million decline in Asia sales due to a strategic reduction in non-spine revenue.
- Profitability Improvement: Net loss decreased significantly by 54.5% compared to Q1 2006. Operating loss narrowed by $0.5 million.
- Expense Fluctuations:
- R&D: Increased 108% ($0.8 million) due to hiring 10 new positions and Scientific Advisory Board costs.
- Sales & Marketing: Increased 20.8% ($1.4 million) driven by higher commissions and compensation.
- G&A: Decreased 21.0% ($1.6 million) due to back-office consolidation and a $0.6 million adjustment to stock-based compensation expense.
- Interest Expense: Decreased by $1.2 million primarily due to the revaluation of a put right related to Alphatec Pacific.
Guidance, Outlook, Risks, and Unusual Items
- Liquidity: Management believes current cash, IPO proceeds, and credit facilities are sufficient to fund operations through 2007. However, the company anticipates continuing net losses for the foreseeable future.
- Debt Covenants: The company was not in compliance with covenants under its $10 million Bank of the West credit facility as of March 31, 2007, but obtained a waiver in May 2007. No borrowings were outstanding under this facility at quarter-end.
- Strategic Transactions:
- Terminated a proposed acquisition of Scient'x S.A. in January 2007, incurring $2.0 million in expenses.
- Executed three license agreements with Scient'x for U.S. rights to specific spinal technologies, including a $2.6 million upfront payment.
- Settled an indemnification claim from the 2005 Alphatec Spine acquisition for $1.0 million (reducing goodwill).
- Legal Proceedings:
- Patent Infringement: Sued by Biedermann Motech GmbH and DePuy Spine regarding pedicle screw patents. A preliminary injunction was denied; Alphatec filed for summary judgment.
- Royalty Dispute: Sued by four surgeons claiming 6% royalties on polyaxial screw sales. Mediation failed; Alphatec intends to defend vigorously.
- Market Risks: Exposure to foreign currency fluctuations (Japanese Yen) and commodity price changes (titanium, stainless steel), though management deems the latter immaterial.
Investor Verification Checklist
- Covenant Compliance: Verify the status of the Bank of the West credit facility waivers and any potential future breaches.
- Legal Exposure: Monitor the outcomes of the patent infringement suit (Biedermann/DePuy) and the surgeon royalty dispute, as adverse rulings could impact operations or require significant payments.
- Scient'x Integration: Assess the commercial viability and royalty obligations associated with the new $2.6 million license agreements following the failed acquisition.
- Cash Burn Rate: Review the $4.9 million net cash used in operating activities against current cash reserves ($8.1 million) to validate the "through 2007" liquidity assertion.
- Inventory Reserves: Confirm the adequacy of the $10.5 million excess and obsolete inventory reserve given the company's focus on shifting away from non-spine products.